Selective serotonin reuptake inhibitor use in pregnant women; pharmacogenetics, drug-drug interactions and adverse effects

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Expert Opinion on Drug Metabolism & Toxicology

• Publication date

  2018-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/17425255.2018.1430139PMID 29345153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Pharmacokinetics and Drug Interactions

  2018influential reference
• Selective Serotonin Reuptake Inhibitors during Pregnancy: Do We Have Now More Definite Answers Related to Prenatal Exposure?

  2017cited by this paper
• Prenatal exposure to selective serotonin reuptake inhibitors and non-verbal cognitive functioning in childhood

  2017cited by this paper
• Prenatal anxiety effects: A review.

  2017cited by this paper
• SSRI and SNRI use during pregnancy and the risk of persistent pulmonary hypertension of the newborn

  2017cited by this paper
• The Association Between Antenatal Exposure to Selective Serotonin Reuptake Inhibitors and Autism: A Systematic Review and Meta-Analysis.

  2017cited by this paper
• Neurobehavioral risks of SSRIs in pregnancy: Comparing human and animal data.

  2017cited by this paper
• Review of Prenatal Maternal Mental Health and the Development of Infant Temperament

  2017cited by this paper
• Impact of an Interaction Between Clopidogrel and Selective Serotonin Reuptake Inhibitors.

  2017cited by this paper
• Maternal SSRI exposure increases the risk of autistic offspring: A meta-analysis and systematic review

  2017cited by this paper
• Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis

  2017cited by this paper
• Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study

  2017influential reference
• Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants in Pregnancy and Congenital Anomalies: Analysis of Linked Databases in Wales, Norway and Funen, Denmark

  2016cited by this paper
• Absence of evidence for increase in risk for autism or attention-deficit hyperactivity disorder following antidepressant exposure during pregnancy: a replication study

  2016cited by this paper
• Serotonin syndrome: Preventing, recognizing, and treating it

  2016cited by this paper
• Antipsychotic Use in Pregnancy and the Risk for Congenital Malformations.

  2016cited by this paper
• Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring.

  2016cited by this paper
• Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: A systematic review and meta-analysis.

  2016cited by this paper
• Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and risk of preterm birth: a systematic review and meta‐analysis

  2016cited by this paper
• Selective serotonin reuptake inhibitors and congenital heart anomalies: comparative cohort studies of women treated before and during pregnancy and their children.

  2016cited by this paper
• Perinatal anxiety disorder prevalence and incidence.

  2016cited by this paper
• Antidepressant Use During Pregnancy and the Risk of Autism Spectrum Disorder in Children.

  2016cited by this paper
• Autism spectrum disorder and prenatal exposure to selective serotonin reuptake inhibitors: A systematic review and meta-analysis.

  2016cited by this paper
• Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study

  2016cited by this paper
• Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn.

  2015cited by this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

  2015cited by this paper
• Maternal use of selective serotonin reuptake inhibitors and risk of miscarriage - assessing potential biases.

  2015cited by this paper
• Prenatal antidepressant exposure and the risk of autism spectrum disorders in children. Are we looking at the fall of Gods?

  2015cited by this paper
• Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study.

  2015cited by this paper
• Pregnancy Complications Following Prenatal Exposure to SSRIs or Maternal Psychiatric Disorders: Results From Population-Based National Register Data.

  2015cited by this paper
• Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: a systematic review and meta-analysis of observational studies.

  2015cited by this paper
• PharmGKB summary: venlafaxine pathway

  2014cited by this paper
• Prenatal antidepressant exposure is associated with risk for attention deficit-hyperactivity disorder but not autism spectrum disorder in a large health system

  2014cited by this paper
• Prenatal SSRI Use and Offspring With Autism Spectrum Disorder or Developmental Delay

  2014cited by this paper
• Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4

  2014cited by this paper
• Maternal depression, antidepressant prescriptions, and congenital anomaly risk in offspring: a population-based cohort study

  2014cited by this paper
• Increased risk of severe congenital heart defects in offspring exposed to selective serotonin-reuptake inhibitors in early pregnancy – an epidemiological study using validated EUROCAT data

  2014cited by this paper
• Selective serotonin reuptake inhibitors in human pregnancy: on the way to resolving the controversy.

  2014cited by this paper
• Exposure to Selective Serotonin Reuptake Inhibitors in Early Pregnancy and the Risk of Miscarriage

  2014cited by this paper
• Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes.

  2014cited by this paper
• Selective serotonin reuptake inhibitor drug interactions in patients receiving statins.

  2014cited by this paper
• MATERNAL DEPRESSIVE, ANXIOUS, AND STRESS SYMPTOMS DURING PREGNANCY PREDICT INTERNALIZING PROBLEMS IN ADOLESCENCE

  2014cited by this paper
• Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.

  2013cited by this paper
• Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study

  2013cited by this paper
• CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis

  2013cited by this paper
• Basic Review of the Cytochrome P450 System

  2013cited by this paper
• Serotonin Hypothesis of Autism: Implications for Selective Serotonin Reuptake Inhibitor Use during Pregnancy

  2013cited by this paper
• Fetal serotonin signaling: setting pathways for early childhood development and behavior.

  2012cited by this paper
• Live and Non-Live Pregnancy Outcomes among Women with Depression and Anxiety: A Population-Based Study

  2012cited by this paper
• Selective serotonin reuptake inhibitors and risk for major congenital anomalies.

  2012cited by this paper
• Drug interactions in the treatment of depression in patients with ischemic heart disease.

  2012cited by this paper
• Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.

  2012cited by this paper
• Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study

  2012cited by this paper
• Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome

  2011cited by this paper
• Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies

  2011cited by this paper
• Antidepressant use during pregnancy and childhood autism spectrum disorders.

  2011cited by this paper
• Duloxetine

  2011cited by this paper
• Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries

  2011cited by this paper
• Perinatal and early postnatal factors underlying developmental delay and disabilities.

  2011cited by this paper
• Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data

  2010cited by this paper
• Paroxetine exposure during pregnancy and cardiac malformations.

  2010cited by this paper
• Persistent Pulmonary Hypertension of the Newborn Is Associated with Mode of Delivery and Not with Maternal Use of Selective Serotonin Reuptake Inhibitors

  2010cited by this paper
• Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis

  2010cited by this paper
• First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies.

  2010cited by this paper
• Use of antidepressants during pregnancy and the risk of spontaneous abortion

  2010cited by this paper
• Prevention, recognition, and management of serotonin syndrome.

  2010cited by this paper
• Fetal Exposure to Antidepressants and Normal Milestone Development at 6 and 19 Months of Age

  2010cited by this paper
• The expanded biology of serotonin.

  2009cited by this paper
• Placental Transfer of SSRI and SNRI Antidepressants and Effects on the Neonate

  2009cited by this paper
• Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.

  2009cited by this paper
• Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database.

  2009cited by this paper
• Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur.

  2009cited by this paper
• Effect of Cytochrome P450 2D6 Genotype on Maternal Paroxetine Plasma Concentrations during Pregnancy

  2009cited by this paper
• Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy.

  2009cited by this paper
• Antidepressant Use During Pregnancy and the Risk of Preterm Delivery and Fetal Growth Restriction

  2009cited by this paper
• Serotonin syndrome: a case of fatal SSRI/MAOI interaction.

  2009cited by this paper
• Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

  2009cited by this paper
• Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn

  2009cited by this paper
• Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study

  2009cited by this paper
• First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.

  2009cited by this paper
• Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy.

  2009cited by this paper
• Maternal use of selective serotonin re‐uptake inhibitors and persistent pulmonary hypertension of the newborn

  2008cited by this paper
• Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study.

  2008cited by this paper
• Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.

  2008cited by this paper
• Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications

  2008cited by this paper
• Does paroxetine cause cardiac malformations?

  2008cited by this paper
• Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins.

  2008cited by this paper
• Use of antidepressant medications during pregnancy: a multisite study.

  2008cited by this paper
• Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.

  2007cited by this paper
• Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors.

  2007cited by this paper
• First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects.

  2007cited by this paper
• Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects.

  2007cited by this paper
• Increasing use of antidepressants in pregnancy.

  2007cited by this paper
• How to increase serotonin in the human brain without drugs.

  2007cited by this paper
• Selective serotonin reuptake inhibitors and adverse pregnancy outcomes.

  2006cited by this paper
• Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data.

  2006cited by this paper
• Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials.

  2006cited by this paper
• Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn

  2006cited by this paper
• Antidepressant drugs during pregnancy and infant congenital heart defect.

  2006cited by this paper
• Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants.

  2006cited by this paper

• Risk of major congenital malformations and heart defects in pregnancies exposed to first-trimester drugs for depression and co-medications.

  2026cites this paper
• Current treatment options for perinatal depression.

  2026cites this paper
• Global, regional and national trends in the burden of persistent pulmonary hypertension of the newborn and essentials of its management from 1993 to 2023: a scoping review

  2025cites this paper
• Management of Perinatal Mental Health Conditions for the General Obstetrician/Gynecologist

  2025cites this paper
• Role of glucocorticoid- and monoamine-metabolizing enzymes in stress-related psychopathological processes

  2020cites this paper
• SSRIs and SNRIs (SRI) in Pregnancy: Effects on the Course of Pregnancy and the Offspring: How Far Are We from Having All the Answers?

  2019cites this paper
• Impact of selective serotonin reuptake inhibitors (SSRIs) during pregnancy and lactation: a focus on short and long-term vascular effects.

  2018cites this paper
• Maternal SSRIs experience and risk of ASD in offspring: a review.

  2018cites this paper
• Inhibition of cytochrome P450 by proadifen diminishes the excitability of brain serotonin neurons in rats.

  2018cites this paper